Hieff UNICON™ Robust Hotstart Taq DNA Polymerase (20 U/μL）_ 14325ES

Yeasen - Leading Innovation in Molecular Enzymes and Reagents Verified independent store

→

This product is a hot-start DNA polymerase that utilizes two proprietary antibodies for dual blocking. It effectively inhibits both the 5'→3' polymerase activity and the 5'→3' exon uclease activity of Taq DNA polymerase. Upon heating at the pre-denaturation temperature for 30 seconds, the blocking antibodies are completely inactivated, releasing both the DNA polymerase and exonuclease activities. This dual-blocking feature offers a dual advantage: it not only prevents non-specific amplification caused by mismatches or primer-dimers but also inhibits the degradation of probes that can lead to a decrease in fluorescent signal. This dual protection ensures greater stability of in vitro diagnostic reagents during transportation or when used at room temperature. Features Antibody-mediated hot start: Activated by a brief 95 °C incubation (30–60 s) for precise reaction control. High sensitivity & specificity: Reliable target detection with minimal non-specific amplification. Inhibitor tolerant: Performs well in the presence of common inhibitors from blood, swabs, and residual prep reagents (e.g., phenol, alcohol). Components Components No. Name 14325ES76 (1,000 U) 14325ES80 (10,000 U) 14325ES92 (25,000 U) 14325ES93 (100,000 U) 14325 Robust Hotstart Taq (20 U/μL) 50 μL 500 μL 1.25 mL 5 mL Storage This product should be stored at -25~-15℃ for 2 years. Figure 1. Direct Amplification from Swab Samples Nasopharyngeal swabs were vortexed in a direct lysis buffer or diluted in TE buffer to prepare templates at equivalent concentrations. Both were tested using the 14325 qPCR master mix and a leading commercial alternative. Results showed that the 14325 formulation exhibits superior inhibitor tolerance, enabling reliable direct amplification from swab samples without purification. Figure 1. Comparison of direct swab amplification performance: 14325 vs. commercial reagents. 2. Direct Amplification from Plasma Samples Clinical plasma samples were diluted in either plasma itself or TE buffer to match template concentrations. When tested with the 14325 qPCR mix and a commercial reagent, the 14325 system demonstrated significantly better resistance to inhibitors—supporting direct amplification with up to 30% final plasma concentration. Figure 2. Comparison of direct plasma amplification performance: 14325 vs. commercial reagent. Documents: Safety Data Sheet 14325_MSDS_HB260304_EN.PDF Manuals 14325_Manual_Ver.EN20260304.pdf Show more